Core Viewpoint - Shanxi Huaxiang Group Co., Ltd. has successfully issued convertible bonds totaling RMB 800 million, with a six-year term and specific interest rates for each year, aimed at enhancing its financial position and supporting its business operations [2][4][14]. Group 1: Bond Issuance Details - The bond issuance was approved by the board on May 19, 2021, and by the shareholders on June 4, 2021 [2]. - The total face value of the convertible bonds is capped at RMB 800 million, with an actual issuance of 8 million bonds at a face value of RMB 100 each [2][5]. - The bonds were listed for trading on the Shanghai Stock Exchange starting January 20, 2022, under the name "Huaxiang Convertible Bonds" and code "113637" [3]. Group 2: Financial Performance - For the fiscal year 2024, the company reported a revenue of RMB 382,751.87 million, representing a year-on-year increase of 17.28% [16]. - The net profit attributable to shareholders reached RMB 47,055.81 million, reflecting a growth of 20.95% compared to the previous year [15][16]. - The total assets of the company amounted to RMB 608,942.66 million, which is a 14.37% increase from the previous year [16]. Group 3: Use of Proceeds - As of December 31, 2024, the company has utilized RMB 60,721.67 million of the raised funds, with RMB 23,241.43 million invested in the current year [17]. - The company has not changed the intended use of the raised funds, maintaining compliance with the original investment commitments [17]. Group 4: Bondholder Rights and Management - The bondholders have specific rights, including the ability to sell back their bonds to the company under certain conditions, such as when the stock price falls below 70% of the conversion price [12]. - The bond trustee, Guotai Junan Securities Co., Ltd., has been actively monitoring the company's financial health and compliance with the bond agreement [14][19].

股票代码：603112 股票简称：华翔股份 转债代码：113637 转债简称：华翔转债 山西华翔集团股份有限公司 公开发行可转换公司债券 受托管理事务报告 （2024年度） 债券受托管理人 二〇二五年六月 重要声明 本报告依据《公司债券发行与交易管理办法》（以下简称"《管理办法》"）、 《山西华翔集团股份有限公司公开发行可转换公司债券之受托管理协议》（以下 简称"《受托管理协议》"）、《山西华翔集团股份有限公司公开发行可转换公司债 券募集说明书》（以下简称"《募集说明书》"）、《山西华翔集团股份有限公司 2024 年度报告》等相关公开信息披露文件、第三方中介机构出具的专业意见等， 由本次债券受托管理人国泰海通证券股份有限公司（曾用名"国泰君安证券股 份有限公司"，以下简称"国泰海通"）编制。 国泰海通对本报告中所包含的从上述文件中引述内容和信息未进行独立验 证，也不就该等引述内容和信息的真实性、准确性和完整性做出任何保证或承 担任何责任。本报告不构成对投资者进行或不进行某项行为的推荐意见，投资 者应对相关事宜做出独立判断，而不应将本报告中的任何内容据以作为国泰海 通所作的承诺或声明。在任何情况下，投资者依据本 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603112 证券简称：华翔股份公告编号：2025-078 山西华翔集团股份有限公司 董监高减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 董监高持股的基本情况 截至本公告披露日，山西华翔集团股份有限公司（以下简称"公司"）董事、副总经理陆海星先生持有公 司股份785,571股，占公司总股本的0.1457%； 公司董事、董事会秘书张敏先生持有公司股份1,367,565股，占公司总股本的0.2536%； 公司监事会主席马毅光先生持有公司股份907,557股，占公司总股本的0.1683%； 公司副总经理郭永智先生持有公司股份915,536股，占公司总股本的0.1698%。 ● 减持计划的主要内容 自本公告披露日起15个交易日后的3个月内，陆海星先生拟通过集中竞价或大宗交易方式减持公司股 份，减持数量合计不超过196,392股，占公司总股本的0.0364%； 张敏先生拟通过集中竞价或大宗交易方式减持公司股份，减持数量合计不超过 ...

证券代码：603112 证券简称：华翔股份 公告编号：2025-078 山西华翔集团股份有限公司 董监高减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 董监高持股的基本情况 截至本公告披露日，山西华翔集团股份有限公司（以下简称"公司"）董事、 副总经理陆海星先生持有公司股份 785,571 股，占公司总股本的 0.1457%； 公司董事、董事会秘书张敏先生持有公司股份 1,367,565 股，占公司总股本 的 0.2536%； 公司监事会主席马毅光先生持有公司股份 907,557 股，占公司总股本的 0.1683%； 公司副总经理郭永智先生持有公司股份 915,536 股，占公司总股本的 0.1698%。 减持计划的主要内容 自本公告披露日起 15 个交易日后的 3 个月内，陆海星先生拟通过集中竞价 或大宗交易方式减持公司股份，减持数量合计不超过 196,392 股，占公司总股本 的 0.0364%； 张敏先生拟通过集中竞价或大宗交易方式减持公司股份，减持数量合计不超 过 341,8 ...

Summary of Key Points Core Viewpoint - Huaxiang Co., Ltd. (603112) announced that several executives plan to reduce their shareholdings due to personal financial needs, with specific percentages outlined for each individual [1]. Executive Shareholding Reduction - The company's Vice President, Lu Haixing, intends to reduce his holdings by up to 0.0364% [1] - Board Secretary, Zhang Min, plans to reduce his holdings by up to 0.0634% [1] - Chairman of the Supervisory Board, Ma Yiguang, aims to reduce his holdings by up to 0.0421% [1] - Vice President, Guo Yongzhi, is set to reduce his holdings by up to 0.0425% [1] Reduction Method and Timeline - The share reduction will be executed through centralized bidding or block trading [1] - The reduction period is scheduled from July 16, 2025, to October 15, 2025 [1]

Group 1 - Beixin Road and Bridge's application for issuing shares to specific targets has been approved by the Shenzhen Stock Exchange, pending approval from the China Securities Regulatory Commission [1] - Wangbian Electric's shareholders plan to reduce their holdings by a total of up to 2.99% of the company's shares, with specific reductions detailed for each shareholder [1] - Guotou Zhonglu is planning a major asset restructuring, leading to a suspension of its stock trading for up to 10 trading days [2] Group 2 - Baiotai has signed a licensing agreement with SteinCares for the commercialization of BAT2406 in Brazil and Latin America, with total payments potentially reaching up to $10 million [3] - Dongfang Bio has obtained two medical device registration certificates for its products, which are valid until June 1, 2030 [4] - Pulaike's subsidiary has received a new veterinary drug registration certificate [5] Group 3 - Wanyi Technology has signed an agreement to establish a joint laboratory with the Energy Research Institute, with a total research and development budget of 6 million yuan [6] - Yingboer plans to use up to 300 million yuan of idle funds for financial management [7] - Blue Biological has received two new veterinary drug registration certificates [8] Group 4 - Jinkai New Energy intends to inject up to 1.247 billion yuan into its wholly-owned subsidiary to enhance its operational capabilities [9] - China Pacific Insurance's assistant general manager's qualification has been approved [10] - Zhaoyan New Drug is reducing its registered capital and notifying creditors [11] Group 5 - Weili Medical plans to invest 37.5 million yuan in establishing a medical industry investment fund [12] - Hongbai New Materials has signed a deposit agreement for idle raised funds [13] - Tongyou Technology is applying for a credit limit of 10 million yuan from a bank [14] Group 6 - Warner Pharmaceutical's subsidiary has received approval for its magnesium sulfate raw material drug [15] - Fuda Co. plans to establish a wholly-owned subsidiary with a capital contribution of 475 million yuan [16] - Yabao Pharmaceutical has obtained a loan commitment letter for stock repurchase of up to 90 million yuan [17] Group 7 - Zhongyin Securities' chairman has resigned due to work adjustments [18] - Aili Home has terminated its share reduction plan ahead of schedule [19] - Samsung New Materials has appointed a new financial officer [20] Group 8 - Guobang Pharmaceutical's subsidiary has received EU GMP certification for its product [21] - Yipin Hong has received a drug registration certificate for its injection solution [22] - Wenzhou Hongfeng's subsidiary has obtained a utility model patent certificate [23] Group 9 - Cangge Mining plans to sign a financial service agreement with Zijin Mining Group [24] - Naipu Mining's application for convertible bonds has been accepted by the Shenzhen Stock Exchange [25] - Shenyang Machine Tool has completed its major asset restructuring [26] Group 10 - Xinlaifu plans to distribute a cash dividend of 5 yuan per 10 shares [27] - Jiashitang plans to distribute a cash dividend of 1.7 yuan per 10 shares [28] - Manbuer plans to distribute a cash dividend of 2.5 yuan per 10 shares [29] Group 11 - Guo Wang Yingda plans to distribute a cash dividend of 0.51 yuan per 10 shares [30] - Changsha Bank's shareholder plans to reduce holdings by up to 0.92% [31] - Hu Nong Commercial Bank plans to distribute a cash dividend of 1.93 yuan per 10 shares [32] Group 12 - Huaxiang Co. plans to distribute a cash dividend of 1.17 yuan per 10 shares [33]

证券代码：603112 证券简称：华翔股份 公告编号：2025-077 山西华翔集团股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 每股分配比例 A 股每股现金红利0.117元（含税） ? 相关日期 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 13 日的2024年年度股东大会审议通过。 股份类别 股权登记日 最后交易日 除权（息）日 现金红利发放日 A股 2025/6/27 － 2025/6/30 2025/6/30 ? 差异化分红送转： 否 （2）派送红股或转增股本的，由中国结算上海分公司根据股权登记日上海证 券交易所收市后登记在册股东持股数，按比例直接计入股东账户。 限售流通股股东由公司自行发放。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公 司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 本次利润分配以方案实施前的公司总股本539,170,563股为基数，每股派发现 金红利0.117 ...

Core Viewpoint - The company has adjusted its total cash dividend distribution for the fiscal year 2024 due to changes in the total share capital resulting from the conversion of convertible bonds [1][4]. Summary by Sections Adjustment of Dividend Distribution - The total cash dividend amount has been adjusted from RMB 55,058,459.16 (including tax) to RMB 63,082,955.87 (including tax) [1][4]. - The adjustment is based on maintaining the per-share distribution ratio, despite changes in the total share capital due to the conversion of convertible bonds [1][4]. Previous Dividend Distribution Plan - The initial plan proposed a cash dividend of RMB 1.17 per 10 shares (including tax), with a total of 470,585,121 shares as of March 31, 2025, leading to a total proposed cash dividend of RMB 201,408,296.78, which represents a percentage of the net profit attributable to shareholders [1][2]. Current Share Capital and Dividend Ratio - As of the announcement date, the total share capital has increased to 539,170,563 shares due to the conversion of 68,585,442 shares from convertible bonds [3][4]. - The total cash dividend for the fiscal year 2024, including previously distributed dividends, now amounts to RMB 209,432,793.49, which is 44.51% of the net profit attributable to shareholders [4].

证券代码：603112 证券简称：华翔股份 公告编号：2025-076 山西华翔集团股份有限公司 关于调整 2024 年度利润分配总额的公告 如在利润分配预案披露之日起至实施权益分派股权登记日期间，因可转债转 股/回购股份/股权激励授予股份回购注销/重大资产重组股份回购注销等致使公 司总股本发生变动的，公司拟维持每股分配比例不变，相应调整分配总额。 具 体 内 容 详 见 公 司 于 2025 年 4 月 18 日 在 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）刊登的《山西华翔集团股份有限公司关于 2024 年度利润分 配预案的公告》（公告编号：2025-023）。 二、调整后利润分配方案 公司于 2021 年 12 月 22 日公开发行的可转换公司债券"华翔转债"自 2022 年 6 月 28 日起可转换为本公司股份。公司股票自 2025 年 3 月 21 日至 2025 年 4 月 25 日，在连续二十五个交易日中已有十五个交易日的收盘价不低于当期转股 价格 11.65 元/股的 130%，即 15.15 元/股。根据《山西华翔集团股份有限公司公 开发行可转换公司债券募集说明书》 ...

证券代码：603112 证券简称：华翔股份 公告编号：2025-077 山西华翔集团股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.117元（含税） 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | A 股 | 2025/6/27 | － | 2025/6/30 | 2025/6/30 | 差异化分红送转： 否 一、 通过分配方案的股东大会届次和日期 3. 分配方案： 本次利润分配方案经公司2025 年 5 月 13 日的2024年年度股东大会审议通过。 二、 分配方案 1. 发放年度：2024年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公 司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 本次利润分配以方案实施前的公司总股本539,170,56 ...